The Quantellect read.As of Nov 19, 2026, 8 active firms cover Viking Therapeutics Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $65.00 to $125.00, a moderate spread. The average target of $96.75 sits 270% above the current $26.17. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.36 next quarter toward $-5.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$96.75
+269.7% upside
Average target across 8 active firms as of Nov 19, 2026 vs $26.17 current
Highest Target$125.00
Average Target$96.75
Lowest Target$65.00
Detailed analyst forecasts for VKTX
Showing 1–7 of 7 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate VKTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VKTX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.36
Range $-1.71 – $-1.12 · 7 analysts · -1% YoY
Next period, 7 analysts expect Viking Therapeutics Inc to earn $-1.36 a share (range $-1.71 – $-1.12), versus $-1.37 a year earlier. Full-year consensus is $-5.31, growing to $-5.21 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Viking Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VKTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$96.00+266.8% to target
Overall win rate
49%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$101.00+285.9% to target
Overall win rate
43%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$106.00+305.0% to target
Overall win rate
44%
+ Follow
#4
George Farmer
Scotiabank · Rank #311
Buy
$102.00+289.8% to target
Overall win rate
44%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$102.00+289.8% to target
Overall win rate
34%
+ Follow
VKTX stock forecast FAQ
What is VKTX's average 12-month price target?+
The 8 active firms with a live target average $96.75 for Viking Therapeutics Inc over the next 12 months, ranging from a $125.00 high to a $65.00 low, as of Nov 19, 2026.
Is VKTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VKTX?+
The Street-high target is $125.00 (BTIG), and the Street-low is $65.00 (JP Morgan). The average of all 8 active-firm targets is $96.75.
How many active Wall Street firms cover VKTX?+
8 active firms have a recognized rating on Viking Therapeutics Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VKTX?+
Among analysts who currently cover VKTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $96.00 target.
What is Viking Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.36 per share (range $-1.71 – $-1.12) across 7 analysts. Full-year EPS is projected at $-5.31, rising to $-5.21 the following year.
How much revenue is Viking Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VKTX lately?+
As of Nov 19, 2026, 8 of 8 active firms rate VKTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VKTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.